DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Montelukast in Acute RSV Bronchiolitis

Information source: Ziv Hospital
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bronchiolitis

Intervention: Montelukast (Drug); Placebo granules (Drug)

Phase: N/A

Status: Completed

Sponsored by: Ziv Hospital

Official(s) and/or principal investigator(s):
Israel Amirav, MD, Principal Investigator, Affiliation: Ziv Medical Center

Summary

There is evidence of inflammatory mechanisms in RSV bronchiolitis with increased

cysteinyl-leukotrienes (cys-LT). Recently, specific cys-LT receptor antagonists - montelukast

(Singulair©) approved for use in infants as granule sachets, have become available. We evaluated the effect of Singulair© on clinical progress and on cytokine profiles in the acute phase of RSV bronchiolitis.

Clinical Details

Official title: A Double-Blind Placebo Controlled Randomized Trial of Montelukast in Acute Respiratory Syncytial Virus Bronchiolitis

Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Length of stay

Eligibility

Minimum age: N/A. Maximum age: 2 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age > 4 weeks < 2 years

- Duration of respiratory symptoms < 4 days

- Signs of bronchiolitis: prodromal rhinorrhea and cough, followed by at least two of

the following signs: chest retractions, tachypnea, wheezing, or rales

- First episode of wheezing or shortness of breath

- Randomization within 12 hours of admission

- No need for steroid treatment in the ward

- Informed consent

Exclusion Criteria:

- A history of asthma symptoms or any previous hospital admissions with respiratory

tract illnesses and if they had ever been treated with anti-asthma medications (prior to the current illness).

- Underlying cardiopulmonary disease such as bronchopulmonary dysplasia, congenital

heart disease, immunodeficiency, or cystic fibrosis.

Locations and Contacts

Additional Information

Starting date: January 2006
Last updated: September 4, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008